Long Term Follow up in Sickle Cell Patients Treated by Hydroxyurea
NCT ID: NCT00480974
Last Updated: 2009-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2007-05-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease
NCT00305175
Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease
NCT01389024
Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia
NCT00001197
Optimizing the Management of Sickle Cell Patients on Hydroxyurea: The Value of Therapeutic Pharmacological Monitoring
NCT06464458
Hydroxyurea and Transfusion
NCT03644953
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A long term follow up will be recorded in a cohort of twenty SCA patients treated by Hydroxyurea for a period between 5 to 12 years. The frequency of vaso-occlusive crises, acute chest syndrome, blood transfusions, and hospitalization will be recorded retrospectively. Also the mean hgb level and hgb F percentage will be summarized.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Patients with Sickle cell anemia treated by Hydroxyurea
Clinical follow up and laboratory analysis
Clinical follow up and laboratory analysis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clinical follow up and laboratory analysis
Clinical follow up and laboratory analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
5 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HaEmek Medical Center, Israel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pediatric Hematology Unit - HaEmek Medical Center - Afula - Israel
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ariel Koren, MD
Role: STUDY_DIRECTOR
Pediatric Hematology Unit, Ha'Emek Medical Center
Carina Levin, MD
Role: STUDY_CHAIR
Pediatric Hematology Unit - Ha'Emek Medical Center
Miri Golan, Student
Role: PRINCIPAL_INVESTIGATOR
Pediatric Hematology Unit - HaEmek Medical Center
Luci Zalman, PhD
Role: STUDY_CHAIR
Hematology Laboratory - HaEmek Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pediatric Hematology Unit - HaEmek Medical Center
Afula, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
5321006.EMC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.